$DH

Definitive Healthcare Corp. (DH) Q2 Earnings and Revenues Top Estimates

Definitive Healthcare (DH) delivered earnings and revenue surprises of +40.00% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Aug 7, 2025, 10:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Definitive Healthcare Corp. (DH) Q2 Earnings and Revenues Top Estimates — source image
Decision brief

The 30-second read

$DHBullishMed
01

Why it matters

The earnings surprise suggests improved market confidence, potentially leading to short-term stock appreciation.

02

Market read

The positive earnings report enhances DH's short-term outlook, with sector implications supporting healthcare tech stocks.

03

What to watch

Market-wide volatility or macroeconomic factors could offset sector gains; earnings are just one piece of the puzzle.

Timing: Immediate, given recent earnings release.

Background

Definitive Healthcare reported Q2 2025 earnings surpassing estimates, driven by operational efficiencies and increased demand.

Company-level read

Ticker impact

$DHBullishHigh confidence
Context

Primary focus due to recent earnings beat.

Expected impact

Potential short-term upward movement; long-term trend uncertain without further data.

Evidence & confidence

Strong earnings beat and positive revenue surprise are typically bullish signals, supported by high relevance and recent positive earnings data.

Market effects

Potential positive impact on healthcare technology sector due to strong earnings.

Limited regional impact; primarily affects US-based healthcare stocks.

Moderate; reflects sector strength but limited global influence.

Counterpoint

The earnings beat may already be priced in; a correction could occur if future earnings disappoint.

Key entities

  • Definitive Healthcare

    A healthcare information services company.

  • Zacks Equity Research

    Financial news and analysis provider.

Related articles

$DHMedAI 8/10

Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

$DHHigh

Definitive Healthcare Corp. (DH): Results of Operations and Financial Condition

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dh-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Hea

$JNJMedAI 8/10

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson (JNJ) proposed a $5.5B settlement for 76,000 talc-related lawsuits, but it requires 95% claimant approval and may exceed this amount. The company has $21B in cash and expects to pay $3B in 2027, with further payments starting in 2028. A judge's recent ruling may strengthen JNJ's legal position. Investors weigh the benefit of reduced uncertainty against potential higher costs.

$CRWDMed

Analysts Back CrowdStrike, Dell and SanDisk Growth

Wall Street analysts maintain positive outlooks on CrowdStrike, Dell, and SanDisk, citing long-term growth in cybersecurity, AI infrastructure, and storage. CrowdStrike's price target raised to $245 by Truist, Dell's to $550 by Evercore, and SanDisk's to $2,250 by J.P. Morgan, all with buy ratings.

$PBRMed

Pemex and Petrobras Bet Big on High-Risk High-Reward Drilling Off Mexico

Pemex and Petrobras are collaborating to explore deep, high-risk oil prospects in the Gulf of Mexico. Pemex, facing declining production and high debt, seeks to unlock potential resources in Jurassic formations. Petrobras, with extensive pre-salt drilling experience, brings technical expertise. Success could reverse Pemex's fortunes, but risks remain high. Pemex reported a 70% net profit drop in Q2 2024, producing 1.66 million bpd, below government targets.